速递｜银诺医药最新！依苏帕格鲁肽α减重IIb期研究达主要终点

Core Viewpoint - The article highlights the significant progress made by the company in the development of its long-acting GLP-1 receptor agonist, Isu-Paglutide α, for weight management in overweight and obese populations, demonstrating promising results in clinical trials [4][6]. Group 1: Clinical Trial Results - The ENLIGHT study, a Phase IIb clinical trial, showed that Isu-Paglutide α achieved its primary endpoint, with significant weight loss observed in all dosage groups compared to the placebo, particularly a 10.58% reduction in the 20 mg once-weekly group after 18 weeks [4][6]. - The study included 200 overweight and obese adults without diabetes, utilizing a randomized, double-blind, placebo-controlled, multi-center design, confirming the drug's efficacy and safety [6]. - Improvements were noted in metabolic parameters, including waist circumference and visceral fat, with no instances of hypoglycemia reported during the trial [6][8]. Group 2: Safety and Tolerability - The trial reported good safety and tolerability, with no participants withdrawing due to adverse events, indicating a favorable safety profile for Isu-Paglutide α [8]. - Gastrointestinal adverse reactions were mostly mild to moderate and transient, resolving on their own [6]. Group 3: Future Development and Market Potential - The success of the Phase IIb study is seen as a milestone for the company, reinforcing the strength of its R&D platform and the potential of its development pipeline [9]. - The company aims to accelerate communication with regulatory authorities and advance global multi-center clinical research to provide better treatment options for obesity patients worldwide [9].